CRANBURY, N.J., Sept. 10 /PRNewswire-FirstCall/ -- Amicus Therapeutics today announced that the Company’s president and chief executive officer, John F. Crowley, will be presenting at the upcoming Morgan Stanley Global Healthcare Unplugged Conference. Mr. Crowley’s presentation is scheduled to begin on Monday, September 14 at 5:05 p.m. EDT.
About Amicus Therapeutics
Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs.
Amicus Therapeutics
